<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2020-3804</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-3804</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОЦЕНКА РИСКА</subject></subj-group></article-categories><title-group><article-title>Маркеры сердечно-сосудистого риска у женщин с метаболическим синдромом в периоде менопаузального перехода на фоне применения мультимодальных нелекарственных терапевтических стратегий</article-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular risk markers in women with metabolic syndrome at the menopausal transition using multimodal non-drug therapies</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2193-5468</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бериханова</surname><given-names>Р. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Berikhanova</surname><given-names>R. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бериханова Румиса Рамзановна — кандидат медицинских наук, врач акушер-гинеколог; соискатель кафедры интегративной медицины</p><p>Москва</p></bio><bio xml:lang="en"><p>Berikhanova Rumisa R. — MD, PhD, obstetrician-gynecologist  Central Clinical Hospital of Civil Aviation; Applicant, Department of Integrative Medicine</p><p>Moscow</p></bio><email xlink:type="simple">rumiska07@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6766-8764</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Миненко</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Minenkoa</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Миненко Инесса Анатольевна — доктор медицинских наук, профессор кафедры интегративной медицины</p><p>Москва</p></bio><bio xml:lang="en"><p>Minenko Inessa A. — MD, professor of the department of integrative medicine</p><p>Moscow</p></bio><email xlink:type="simple">kuz-inna@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3912-4003</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бондарев</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Bondarev</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бондарев Сергей Анатольевич — доктор медицинских наук, профессор кафедры спортивной медицины и медицинской реабилитации</p><p>Москва</p></bio><bio xml:lang="en"><p>Bondarev Sergey A. — MD, professor of the Department of Sports Medicine and Medical Rehabilitation</p><p>Moscow</p></bio><email xlink:type="simple">sabondarev@yandex.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФБУ Центральная клиническая больница гражданской авиации;&#13;
ФГАОУ ВО Первый Московский государственный&#13;
 медицинский университет имени И.М. Сеченова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Central Clinical Hospital of Civil Aviation;&#13;
I.M. Sechenov First Moscow State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГАОУ ВО «Первый Московский государственный&#13;
 медицинский университет имени И.М. Сеченова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГАОУ ВО Первый Московский государственный&#13;
 медицинский университет имени И.М. Сеченова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>11</day><month>06</month><year>2020</year></pub-date><volume>25</volume><issue>6</issue><fpage>3804</fpage><lpage>3804</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Бериханова Р.Р., Миненко И.А., Бондарев С.А., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Бериханова Р.Р., Миненко И.А., Бондарев С.А.</copyright-holder><copyright-holder xml:lang="en">Berikhanova R.R., Minenkoa I.A., Bondarev S.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/3804">https://russjcardiol.elpub.ru/jour/article/view/3804</self-uri><abstract><sec><title>Цель</title><p>Цель. Изучить влияние немедикаментозной коррекции на основные маркеры сердечно-сосудистого риска (ССР) у женщин с климактерическими расстройствами на фоне метаболического синдрома (МС).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. 330 женщин 45-50 лет с климактерическими расстройствами в периоде менопаузального перехода и МС ранжировано на 5 групп. В группе I применялись: базовое лечение, лечебная физкультура, бальнеотерапия, прием поливитаминов и минералов, а также физиотерапевтические факторы (вибротерапия, хромотерапия, мелотерапия, ароматерапия, аэроионотерапия). В группе II из перечисленных методов исключалась хромотерапия, в группе III — вибротерапия, в группе IV физиотерапия не применялась, в группе V использовалось только базовое лечение. Проводилось измерение артериального давления (АД), исследовалась липидограмма, определялись уровни глюкозы, инсулина сыворотки крови, индекс HOMA-IR (Homeostasis Model Assessment — Insulin Resistance).</p></sec><sec><title>Результаты</title><p>Результаты. Комплексное лечение с применением физических факторов способствовало оптимизации контроля АД, улучшило показатели углеводного и жирового обмена. Одновременное использование всех перечисленных физических факторов позволило улучшить контроль за уровнем АД, наиболее существенно снизить через 6 мес. терапии у пациенток с климактерическим синдромом легкой степени тяжести индекс HOMA-IR — на 56,2%, индекс атерогенности — на 31,2%, у пациенток с климактерическим синдромом средней степени тяжести — на 57,2% и 30,5%, соответственно (р&lt;0,0001). Снижение общего балла теста Грина составило, соответственно, 55,3% и 39,9% (р&lt;0,0001).</p></sec><sec><title>Заключение</title><p>Заключение. Немедикаментозные программы коррекции с физиотерапией способствуют снижению выраженности факторов ССР у женщин с МС в периоде менопаузального перехода, положительно воздействуя на модифицируемые факторы в ассоциации с нормализацией деятельности гипоталамо-гипофизарно-яичниковых взаимоотношений. Приоритетным является одновременное использование вибротерапии, хромотерапии, мелотерапии, ароматерапии и аэроионотерапии.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To study the effect of non-drug strategies on the main markers of cardiovascular risk in women with menopausal disorders and metabolic syndrome (MS).</p></sec><sec><title>Material and methods</title><p>Material and methods. Three hundred women aged 45-50 years with disorders during the menopausal transition and MS were ranked in 5 groups. In group I, following methods were used: standard treatment, physiotherapy, balneotherapy, multivitamins and minerals, as well as physical factors (vibration therapy, chromotherapy, melotherapy, aromatherapy, aeroionotherapy). In group II, chromotherapy was excluded from the above methods, in group III — vibration therapy, in group IV, physiotherapy was not used, in group V only standard treatment was used. We assessed blood pressure (BP), lipid profile, levels of glucose and serum insulin, and estimated the HOMA-IR index (Homeostasis Model Assessment — Insulin Resistance).</p></sec><sec><title>Results</title><p>Results. Complex treatment using physical factors contributed to the optimization of BP control, improved carbohydrate and fat metabolism. The simultaneous use of all the above physical factors made it possible to improve BP control and most significantly reduce after 6 months of therapy in patients with mild climacteric syndrome the HOMAIR index by 56,2% and the atherogenic index by 31,2%, and in patients with moderate climacteric syndrome — by 57,2% and 30,5%, respectively (p&lt; 0,0001). The decrease in the Green test was 55,3% and 39,9%, respectively (p&lt;0,0001).</p></sec><sec><title>Conclusion</title><p>Conclusion. Non-drug strategies with physiotherapy help to reduce the manifestation of cardiovascular risk in women with MS at the menopausal transition, positively affecting modifiable factors and normalizing the activity of hypothalamicpituitary-gonadal axis. The priority is the simultaneous use of vibration therapy, chromotherapy, melotherapy, aromatherapy and aeroionotherapy.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>климактерический синдром</kwd><kwd>метаболический синдром</kwd><kwd>сердечно-сосудистый риск</kwd><kwd>физиотерапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>climacteric syndrome</kwd><kwd>metabolic syndrome</kwd><kwd>cardiovascular risk</kwd><kwd>physiotherapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Huang Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematicreview and meta-analysis. BMJ. 2016;355(i5953):1-11. doi:10.1136/bmj.i5953.</mixed-citation><mixed-citation xml:lang="en">Huang Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematicreview and meta-analysis. BMJ. 2016;355(i5953):1-11. doi:10.1136/bmj.i5953.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Eshtiaghi R, Esteghamati A, Nakhjavani M. Menopause is an independent predictor of metabolic syndrome in Iranian women. Maturitas. 2010;65(3):262-6. doi:10.1016/j.maturitas.2009.11.004.</mixed-citation><mixed-citation xml:lang="en">Eshtiaghi R, Esteghamati A, Nakhjavani M. Menopause is an independent predictor of metabolic syndrome in Iranian women. Maturitas. 2010;65(3):262-6. doi:10.1016/j.maturitas.2009.11.004.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Mumusoglu S, Yildiz BO. Metabolic Syndrome During Menopause. Curr Vasc Pharmacol. 2019;17(6):595-603. doi:10.2174/1570161116666180904094149.</mixed-citation><mixed-citation xml:lang="en">Mumusoglu S, Yildiz BO. Metabolic Syndrome During Menopause. Curr Vasc Pharmacol. 2019;17(6):595-603. doi:10.2174/1570161116666180904094149.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Cengiz H, Kaya C, Suzen Caypinar S, Alay I. The relationship between menopausal symptoms and metabolic syndrome in postmenopausal women. J Obstet Gynaecol. 2019;39(4):529-33. doi:10.1080/01443615.2018.1534812.</mixed-citation><mixed-citation xml:lang="en">Cengiz H, Kaya C, Suzen Caypinar S, Alay I. The relationship between menopausal symptoms and metabolic syndrome in postmenopausal women. J Obstet Gynaecol. 2019;39(4):529-33. doi:10.1080/01443615.2018.1534812.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Tuomikoski P, Savolainen-Peltonen H. Vasomotor symptoms and metabolic syndrome. Maturitas. 2017;97:61‐5. doi:10.1016/j.maturitas.2016.12.010.</mixed-citation><mixed-citation xml:lang="en">Tuomikoski P, Savolainen-Peltonen H. Vasomotor symptoms and metabolic syndrome. Maturitas. 2017;97:61‐5. doi:10.1016/j.maturitas.2016.12.010.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Willi J, Ehlert U. Assessment of perimenopausal depression: A review. J Affect Disord. 2019;249:216-22. doi:10.1016/j.jad.2019.02.029.</mixed-citation><mixed-citation xml:lang="en">Willi J, Ehlert U. Assessment of perimenopausal depression: A review. J Affect Disord. 2019;249:216-22. doi:10.1016/j.jad.2019.02.029.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Stute P, Spyropoulou A, Karageorgiou V, et al. Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement. Maturitas. 2020;131:91-101. doi:10.1016/j.maturitas.2019.11.002.</mixed-citation><mixed-citation xml:lang="en">Stute P, Spyropoulou A, Karageorgiou V, et al. Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement. Maturitas. 2020;131:91-101. doi:10.1016/j.maturitas.2019.11.002.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y, Chen Y, Ma L. Depression and cardiovascular disease in elderly: Current understanding. J Clin Neurosci. 2018;47:1-5. doi:10.1016/j.jocn.2017.09.022.</mixed-citation><mixed-citation xml:lang="en">Zhang Y, Chen Y, Ma L. Depression and cardiovascular disease in elderly: Current understanding. J Clin Neurosci. 2018;47:1-5. doi:10.1016/j.jocn.2017.09.022.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Zimmet P, Alberti KGMM, Stern N, et al. The Circadian Syndrome: is the Metabolic Syndrome and much more! J Intern Med. 2019;286(2):181-91. doi:10.1111/joim.12924.</mixed-citation><mixed-citation xml:lang="en">Zimmet P, Alberti KGMM, Stern N, et al. The Circadian Syndrome: is the Metabolic Syndrome and much more! J Intern Med. 2019;286(2):181-91. doi:10.1111/joim.12924.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lemche AV, Chaban OS, Lemche E. Depression contributing to dyslipidemic cardiovascular risk in the metabolic syndrome. J Endocrinol Invest. 2017;40(5):539-46. doi:10.1007/s40618-016-0601-y.</mixed-citation><mixed-citation xml:lang="en">Lemche AV, Chaban OS, Lemche E. Depression contributing to dyslipidemic cardiovascular risk in the metabolic syndrome. J Endocrinol Invest. 2017;40(5):539-46. doi:10.1007/s40618-016-0601-y.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Stevenson JC, Tsiligiannis S, Panay N. Curr Vasc Pharmacol. 2019;17(6):591-4. doi:10.2174/1570161116666181002145340.</mixed-citation><mixed-citation xml:lang="en">Stevenson JC, Tsiligiannis S, Panay N. Curr Vasc Pharmacol. 2019;17(6):591-4. doi:10.2174/1570161116666181002145340.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Chedraui P, Pérez-López FR. Metabolic syndrome during female midlife: what are the risks? Climacteric. 2019;22(2):127-32. doi:10.1080/13697137.2018.1561666.</mixed-citation><mixed-citation xml:lang="en">Chedraui P, Pérez-López FR. Metabolic syndrome during female midlife: what are the risks? Climacteric. 2019;22(2):127-32. doi:10.1080/13697137.2018.1561666.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Marlatt KL, Redman LM, Beyl RA, et al. Racial differences in body composition and cardiometabolic risk during the menopause transition: a prospective, observational cohort study. Am J Obstet Gynecol. 2020;222(4):365.e1-365.e18. doi:10.1016/j.ajog.2019.09.051.</mixed-citation><mixed-citation xml:lang="en">Marlatt KL, Redman LM, Beyl RA, et al. Racial differences in body composition and cardiometabolic risk during the menopause transition: a prospective, observational cohort study. Am J Obstet Gynecol. 2020;222(4):365.e1-365.e18. doi:10.1016/j.ajog.2019.09.051.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Смирнова Е.Н., Турунцева О.Н., Шулькина С.Г. Дисфункция эндотелия у женщин с ожирением в раннем постменопаузальном периоде. Вятский медицинский вестник. 2017;1(53):23-7.</mixed-citation><mixed-citation xml:lang="en">Smirnova EN, Turuntseva ON, Shulkina SG. Endothelial dysfunction in obese women in the early postmenopausal period. Vyatsky Medical Bulletin. 2017;1(53):23-7. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Anti-age-стратегии и менопаузальная гормональная терапия: от регуляции клеточного метаболизма к сохранению качества жизни. Гинекология. 2018;20(3):42-7. doi:10.26442/2079-5696_2018.3.42-47.</mixed-citation><mixed-citation xml:lang="en">Anti-age strategies and menopausal hormone therapy: from the regulation of cell metabolism to maintaining the quality of life. Gynecology. 2018;20(3):42-7. (In Russ.) doi:10.26442/2079-5696_2018.3.42-47.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ward E, Gold EB, Johnson WO, et al. Patterns of Cardiometabolic Health as Midlife Women Transition to Menopause: A Prospective Multiethnic Study. J Clin Endocrinol Metab. 2019;104(5):1404‐12. doi:10.1210/jc.2018-00941.</mixed-citation><mixed-citation xml:lang="en">Ward E, Gold EB, Johnson WO, et al. Patterns of Cardiometabolic Health as Midlife Women Transition to Menopause: A Prospective Multiethnic Study. J Clin Endocrinol Metab. 2019;104(5):1404‐12. doi:10.1210/jc.2018-00941.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Cobin RH, Goodman NF. AACE Reproductive Endocrinology Scientific Committee. American associanione of clinical endocrinologists and American college of endocrinology positione statement on menopause — 2017. Endocr Pract. 2017;23(7):869‐80. doi:10.4158/EP171828.PS.</mixed-citation><mixed-citation xml:lang="en">Cobin RH, Goodman NF. AACE Reproductive Endocrinology Scientific Committee. American associanione of clinical endocrinologists and American college of endocrinology positione statement on menopause — 2017. Endocr Pract. 2017;23(7):869‐80. doi:10.4158/EP171828.PS.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Anagnostis P, Paschou SA, Katsiki N, et al. Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now? Curr Vasc Pharmacol. 2019;17(6):564-72. doi:10.2174/1570161116666180709095348.</mixed-citation><mixed-citation xml:lang="en">Anagnostis P, Paschou SA, Katsiki N, et al. Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now? Curr Vasc Pharmacol. 2019;17(6):564-72. doi:10.2174/1570161116666180709095348.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Oliver-Williams C, Glisic M, Shahzad S, et al. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review. Hum Reprod Update. 2019;25(2):257‐71. doi:10.1093/humupd/dmy039.</mixed-citation><mixed-citation xml:lang="en">Oliver-Williams C, Glisic M, Shahzad S, et al. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review. Hum Reprod Update. 2019;25(2):257‐71. doi:10.1093/humupd/dmy039.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Костромина А.А., Радзинский В.Е., Хамошина М.Б. и др. Факторы риска развития климактерического синдрома тяжелой степени: клинико-статистическое исследование. Доктор. Ру. 2017;9(138):12-6.</mixed-citation><mixed-citation xml:lang="en">Kostromina AA, Radzinsky VE, Khamoshina MB, et al. Risk Factors for Severe Menopausal Syndrome: a Clinicostatistical Study. Doctor.Ru. 2017;9(138):12-6. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Wassertheil-Smoller S, Kaplan RC, Salazar CR. Stroke findings in the Women’s Health Initia-tive. Semin. Reprod. Med. 2014;32(6):438-46. doi:10.1055/s-0034-1384627.</mixed-citation><mixed-citation xml:lang="en">Wassertheil-Smoller S, Kaplan RC, Salazar CR. Stroke findings in the Women’s Health Initia-tive. Semin. Reprod. Med. 2014;32(6):438-46. doi:10.1055/s-0034-1384627.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Юренева С.В., Ермакова Е.И. Ведение женщин с менопаузальными расстройствами (обзор клинических рекомендаций). Проблемы репродукции. 2017;23(5):115-22. doi:10.17116/repro2017235115-122.</mixed-citation><mixed-citation xml:lang="en">Yureneva SV, Ermakova EI. Management of women with menopausal disorders (review of clinical guidelines). Reproduction problems. 2017;23(5):115-22. (In Russ.) doi:10.17116/repro2017235115-122.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Рекомендации экспертов Всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома (второй пересмотр). Практическая медицина. 2010;5(44):81-101.</mixed-citation><mixed-citation xml:lang="en">Recommendations of experts of the All-Russian Scientific Society of Cardiology on the diagnosis and treatment of metabolic syndrome (second revision). Practical medicine. 2010;5(44):81-101. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by Representatives of 10 Societies and by Invited experts) Developed With the Special Contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-2381. doi:10.1093/eurheartj/ehw106.</mixed-citation><mixed-citation xml:lang="en">Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by Representatives of 10 Societies and by Invited experts) Developed With the Special Contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-2381. doi:10.1093/eurheartj/ehw106.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Фролков В.К., Нагорнев С.Н., Бобровницкий И.П. Использование минеральных вод питьевого применения для увеличеняи функциональных резервов и неспецифической резистентности организма. Российский журнал восстановительной медицины. 2017;3:34-61.</mixed-citation><mixed-citation xml:lang="en">Frolkov VK, Nagornev SN, Bobrovnitsky IP. The use of mineral water for drinking use to increase functional reserves and nonspecific resistance of the body. Russian Journal of Rehabilitation Medicine. 2017;3:34-61. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Jamilian M, Sabzevar NK, Asemi Z. The Effect of Magnesium and Vitamin E Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, PlaceboControlled Trial. Horm Metab Res. 2019;51(2):100-5. doi:10.1055/a-0749-6431.</mixed-citation><mixed-citation xml:lang="en">Jamilian M, Sabzevar NK, Asemi Z. The Effect of Magnesium and Vitamin E Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, PlaceboControlled Trial. Horm Metab Res. 2019;51(2):100-5. doi:10.1055/a-0749-6431.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Ko SH, Kim HS. Menopause-Associated Lipid Metabolic Disorders and Foods Beneficial for Postmenopausal Women. Nutrients. 2020;12(1):202. doi:10.3390/nu12010202.</mixed-citation><mixed-citation xml:lang="en">Ko SH, Kim HS. Menopause-Associated Lipid Metabolic Disorders and Foods Beneficial for Postmenopausal Women. Nutrients. 2020;12(1):202. doi:10.3390/nu12010202.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Близниченко М.В. Музыка и музыкотерапия в эволюции человечества. Kant. 2014;3(12):146-8.</mixed-citation><mixed-citation xml:lang="en">Bliznichenko MV. Music and music therapy in the evolution of mankind. Kant. 2014;3(12):146-8. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Roozbeh N, Ghazanfarpour M, Khadivzadeh T, et al. Effect of Lavender on Sleep, Sexual Desire, Vasomotor, Psychological and Physical Symptom among Menopausal and Elderly Women: A Systematic Review. J Menopausal Med. 2019;25(2):88-93. doi:10.6118/jmm.18158.</mixed-citation><mixed-citation xml:lang="en">Roozbeh N, Ghazanfarpour M, Khadivzadeh T, et al. Effect of Lavender on Sleep, Sexual Desire, Vasomotor, Psychological and Physical Symptom among Menopausal and Elderly Women: A Systematic Review. J Menopausal Med. 2019;25(2):88-93. doi:10.6118/jmm.18158.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Schneider R, Singer N, Singer T. Medical aromatherapy revisited-Basic mechanisms, critique, and a new development. Hum Psychopharmacol. 2019;34(1):e2683. doi:10.1002/hup.2683.</mixed-citation><mixed-citation xml:lang="en">Schneider R, Singer N, Singer T. Medical aromatherapy revisited-Basic mechanisms, critique, and a new development. Hum Psychopharmacol. 2019;34(1):e2683. doi:10.1002/hup.2683.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Боряк В.П. Коррекция нарушенного вагосимпатического равновесия с помощью фитоаэроионизации. Курортная медицина. 2013;2:30-3.</mixed-citation><mixed-citation xml:lang="en">Boryak VP. Correction of disturbed vagosympathetic balance with the help of phytoaeroionization. Spa medicine. 2013;2:30-3. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Физиотерапия и курортология. Книга I. Под ред. Боголюбова В.М. М.: Издательский дом БИНОМ, 2018. с. 408. ISBN 978-5-9518-0273-6</mixed-citation><mixed-citation xml:lang="en">Physiotherapy and balneology. Book I. Ed. Bogolyubova V.M. M.: BINOM Publishing House, 2018. p. 408. (In Russ.) ISBN 978-5-9518-0273-6</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
